GLS and colorectal cancer: Finally, two MGPs, “reduced glutathione-KEAP1-glutamate metabolism” from Lung-AdenoCA and “L-leucine-KRAS-transport, extracellular” from ColoRect-AdenoCA, are well aligned with previous drug target suggestions: inhibition of glutaminase in lung adenocarcinoma with KEAP1 mutation [56], and inhibition of LAT1 (or SLC7A5) encoding “solute carrier family 7 member 5” in colorectal cancer with KRAS mutation [57], respectively.